Evidence map›Paper›PMID 24560492›Full record

ArticleSeizure2014

Safety of an intravenous formulation of lamotrigine.

Jeannine M Conway, Angela K Birnbaum, Ilo E Leppik, Page B Pennell, James R White, John O Rarick, Rory P Remmel

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Seizure, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jeannine M ConwayExperimental and Clinical Pharmacology, 308 Harvard Street SE, Minneapolis, MN 55455, United States.
Angela K BirnbaumExperimental and Clinical Pharmacology, 308 Harvard Street SE, Minneapolis, MN 55455, United States. Electronic address: birnb002@umn.edu.
Ilo E LeppikExperimental and Clinical Pharmacology, 308 Harvard Street SE, Minneapolis, MN 55455, United States; Department of Neurology, 420 Delaware St. SE, University of Minnesota, Minneapolis, MN 55455, United States; MINCEP Epilepsy Care, 5775 Wayzata Boulevard, Minneapolis, MN 55416, United States.
Page B PennellDepartment of Neurology and Division of Women's Health at Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, United States.
James R WhiteMINCEP Epilepsy Care, 5775 Wayzata Boulevard, Minneapolis, MN 55416, United States.
John O RarickExperimental and Clinical Pharmacology, 308 Harvard Street SE, Minneapolis, MN 55455, United States.
Rory P RemmelDepartment of Medicinal Chemistry, 308 Harvard Street SE, University of Minnesota, Minneapolis 55455, MN, United States.
University of Minnesota · USBrigham and Women's Hospital · USMinnesota Epilepsy Group · US

Funding

YOUTH DRUG ABUSE, ADHD, AND RELATED DISRUPTIVE DISORDERSM01RR000400 · NCRR · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BACHANOVA, VERONIKA S · 1985 to 2009
$33.7M
X LINKED NYSTAGMUS SYNDROME WITH FEATURES OF ALBINISMM01RR000039 · NCRR · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 1985 to 2007
$21.3M
TREATMENT OF PATIENTS WITH PSEUDO-SEIZURESP50NS016308 · NINDS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BIRNBAUM, ANGELA K · 1985 to 2006
$8.5M
NCRR NIH HHS M01 RR000039NCRR NIH HHS M01-RR00039NCRR NIH HHS M01 RR000400NCRR NIH HHS M01-RR00400NINDS NIH HHS P50 NS016308NINDS NIH HHS P50-NS16308
6 · The paper itself

Abstract

purposeIntravenous (IV) formulations are useful when treating patients where oral administration is not possible and to study certain pharmacokinetic parameters such as bioavailability. We developed a stable-labeled IV formulation of lamotrigine (LTG) for studying pharmacokinetics in epilepsy patients.

methodsStable-labeled IV LTG was given to 20 persons with epilepsy (6 men; 14 women) with a mean age of 34.8 years (SD 11.7). A 50mg dose of LTG (stable labeled) was given intravenously and replaced 50mg of the regular morning oral dose of LTG (unlabeled, commercially available formulation).

resultsNo significant changes in blood pressure, heart rate, or adverse events including rash were attributed to administration of a 50-mg dose of the intravenous LTG formulation.

conclusionOur results show that LTG base that is complexed with 2-hydroxypropyl-β-cyclodextrin and stable-labeled can be given safely as a tracer replacement dose.

Indexed as

2-Hydroxypropyl-beta-cyclodextrinAdministration, OralAdolescentAdultAgedAged, 80 and overAnticonvulsantsbeta-CyclodextrinsDrug Administration ScheduleEpilepsyFemaleHumansLamotrigineMaleMiddle AgedTriazines2-Hydroxypropyl-beta-cyclodextrinAnticonvulsantsbeta-CyclodextrinsLamotrigineTriazinesCyclodextrinEpilepsyIntravenousLamotrigineSafety

Identifiers

PMID24560492
PMCPMC4023538
OpenAlexW2109160231

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.